fbpx
previous arrow
next arrow
Slider

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

IONA® Nx Launch

Manchester, UK – 3 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of IONA® Nx NIPT workflow, the Company’s new innovative non-invasive prenatal test (‘NIPT’). The IONA Nx seeks to offer clinical labs a high performing, flexible, scalable and innovative NIPT service in-house and is developed to run on the Illumina Nextseq 550 Dx platform for next generation sequencing.

As announced on 15 June 2020, the IONA Nx received a CE mark across the European Union, including the UK, as well as other countries that accept the CE-IVD mark. Yourgene will initially transition existing customers in the UK and France, where the Company has an existing direct presence to the IONA Nx. The Company also expects to see uptake of the product in other European territories where it will utilise its recently strengthened commercial team in Europe.

In addition, Yourgene will be targeting additional markets within the Illumina IP territory following regulatory approvals. As announced on 13 August 2020 Australia’s Therapeutics Goods Association (‘TGA’) approved the IONA Nx as a medical device Class 3, allowing Southern Cross Diagnostics, Yourgene’s Australian distributor, to commence sales. Further territories covered by the Illumina licence agreement will also be made available when regulatory submissions are approved.

Illumina’s NGS technology accounts for around 75% of the global NGS market and the NIPT market in Europe alone is set to grow to USD $500 million by 20251 which puts Yourgene in a strong position going forward. The Yourgene NIPT service laboratory in Manchester is in the process of changing over to the IONA Nx and Yourgene will inform customers when this is live.

About IONA Nx
The IONA Nx uses an innovative new fetal fraction enrichment step with the Yourgene QS250 instrument, which enriches fetal fraction by two-fold, reducing the need for as much sequencing and therefore making it a more cost effective NIPT workflow. The Yourgene QS250 is powered by the Ranger® technology, from Coastal Genomics which Yourgene acquired in August 2020. The use of the Yourgene QS250 in an NIPT NGS workflow is an industry step change, the instrument increases cell free fetal DNA enrichment which increases sequencing efficiency and improves the performance of NIPT.

The IONA Nx has a reduced capital footprint with new instrumentation in the workflow and uses the Yourgene SP150 and Yourgene QS250 to combine the DNA extraction, sample preparation and enrichment elements of the workflow ahead of the sequencing step. This is the first time Yourgene will be making the instruments commercially available as part of the workflow and enables customers to obtain the majority of the workflow, including instruments, reagents, bioinformatics software and workflow management systems, from one provider.

There are several unique and new product features to the IONA Nx including >99.99% accuracy (sensitivity and specificity) and an extended clinical menu, offering whole genome analysis including Trisomy 21, 18, 13, Sex chromosomal aneuploidies, other autosomal aneuploidies and optional fetal sex determination, with the intention to add clinically relevant Microdeletions in the near future. The IONA Nx is flexible and scalable which makes it suitable for automated or manual workflow with up to 48 samples per sequencing run and therefore suitable for low to high throughput labs. It is one of the fastest automated workflows on the market and can be performed in just two days, three for manual workflow. The Atlas Workflow Manager, developed by Yourgene, is available for the automated workflow to give complete traceability and can also be customised to integrate with a customer labs own laboratory information management systems (‘LIMS’).

For full details of the IONA Nx please visit: www.yourgene-health.com/nipt/iona-nx 

Lyn Rees, CEO of Yourgene Health plc, stated: “We have already expanded our European sales team with key appointments in UK, France, Germany to support the commercial roll-out of the IONA Nx and we will look to give updates on key milestones such as regulatory approval and new customer wins. Our IONA test has a strong reputation for reliability and accuracy and was the first CE marked NIPT product for the European market. The new IONA Nx combines this gold standard for reliability and accuracy with a market leading sequencer and we believe this will be a strong driver of growth in the future.

“We expect to see accelerated double-digit growth in our NIPT business this calendar year. We are confident that a this will be delivered through a mix of organic growth across our existing NIPT customer base, the transition of existing customers to IONA Nx in current territories, as well through securing new customers and commencing sales in new territories.”

1 https://www.prnewswire.com/news-releases/european-500-million-non-invasive-prenatal-testing-market-to-2025-300728591.html

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Yourgene Health plc

Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 669 8122

This email address is being protected from spambots. You need JavaScript enabled to view it.

Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / James Caithie / Ludovico Lazzaretti

 Tel: +44 (0)20 7213 0880

N+1 Singer (Joint Corporate Broker)
Aubrey Powell / Tom Salvesen / George Tzimas

Tel: +44 (0)20 7496 3000

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Walbrook PR Ltd (Media and Investor Relations)

Paul McManus / Lianne Cawthorne 

Tel: +44 (0)20 7933 8780 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Mob: 07980 541 893 Mob: 07584 391 303   

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.  

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.



  • 21 October 2020 - Yourgene Genomic Services collaboration with Cytox +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services collaboration with Cytox

    Partnership with Cytox to enable clinical access to genoSCORE™ - a new genetic test to determine the risk of developing Alzheimer’s disease

    Manchester, UK – 21 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces a new collaboration between the recently launched Yourgene Genomic Services (“YGS”) and Cytox Ltd (“Cytox”), for a beta-testing genomic study on their

    Read More
  • 12 October 2020 - Elucigene DPYD tests to be used routinely in Wales +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Elucigene DPYD tests to be used routinely in Wales

    Wales is first UK nation to offer DPYD screening to patients undergoing chemotherapy
    DPYD tests screen patients to identify risk of severe side effects from certain chemotherapy treatments

    Manchester, UK – 12 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its oncology product, Elucigene DPYD test, is now being used in Wales to routinely

    Read More
  • 8 October 2020 - Strategic reproductive health partnership secured in Japan +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Strategic reproductive health partnership secured in Japan

    Manchester, UK – 8 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces it has entered into a 5-year strategic partnership with a blue chip Japanese multinational to provide Yourgene’s Flex™ Analysis Software (“ Flex Software”) bioinformatics platform for a reproductive health project.

    Yourgene and the Japanese partner (the “Partner”) have entered into a technology transfer

    Read More
  • 7 October 2020 - IONA® Nx awarded contract with St George’s NHS Hospital +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    IONA ® Nx awarded contract with St George’s NHS Hospital

    Manchester, UK – 7 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has been awarded the contract for non-invasive prenatal testing (NIPT) using its newly-launched IONA ® Nx NIPT Workflow ('IONA ® Nx'), by the prestigious St George’s NHS Trust Foundation in Tooting, South London (“St George’s”). The contract, subject to signing by both

    Read More
  • 28 September 2020 - Launch of Yourgene Genomic Services +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Launch of Yourgene Genomic Services

    Manchester, UK – 28 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of Yourgene Genomic Services, an integration and expansion of the Company’s international service laboratory offerings. Yourgene Genomic Services becomes a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations.

    Yourgene Genomic Services (“YGS”) will bring together

    Read More
  • 24 September 2020 - DPD reimbursement in Germany +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    DPD reimbursement in Germany

    Manchester, UK – 24 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that the German Federal Joint Committee, G-BA, the national reimbursement authority in Germany, has approved the reimbursement for testing of Dihydropyrimidine Dehydrogenase (DPD) deficiency in Germany, which opens up the clinical market in this region for the Company’s first oncology genotyping product, the Elucigene DPYD Test. The

    Read More
  • 22 September 2020 - AGM statement +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    AGM Statement

    Manchester, UK – 22 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be holding its Annual General Meeting (AGM) at 4:00pm today.

    At the meeting, Adam Reynolds, Non-executive Chairman, will make the following statement:

    I am delighted to welcome longstanding and recent shareholders to our AGM. Whilst the pandemic has presented serious challenges to individuals, communities and businesses worldwide, these are

    Read More
  • 21 September 2020 - US distribution agreement for DPYD and other products +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    US distribution agreement for DPYD and other products

    Manchester, UK – 21 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has appointed Immuno-Biological Laboratories Inc (‘IBL-America’), a supplier of in-vitro diagnostic kits for the medical device and research industry, as a non-exclusive distributor for several PCR (‘polymerase chain reaction’) tests across Yourgene’s reproductive health and oncology portfolios in the US.

    The

    Read More
  • 3 September 2020 - IONA® Nx Launch +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    IONA ® Nx Launch

    Manchester, UK – 3 September 2020:  Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of IONA ® Nx NIPT workflow, the Company’s new innovative non-invasive prenatal test (‘NIPT’). The IONA Nx seeks to offer clinical labs a high performing, flexible, scalable and innovative NIPT service in-house and is developed to run on the Illumina Nextseq 550 Dx platform for next generation

    Read More
  • 13 August 2020 - TGA approves IONA® Nx for sale in Australia +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    TGA approves IONA ® Nx for sale in Australia

    Manchester, UK – 13 August 2020:  Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its IONA ® Nx NIPT workflow (‘IONA ® Nx’), a non-invasive prenatal test (‘NIPT’), has been approved by Australia’s Therapeutics Goods Association (‘TGA’) as a medical device Class 3, allowing Southern Cross Diagnostics, Yourgene’s Australian distributor, to commence sales.

    The TGA is the regulatory

    Read More
  • 5 August 2020 - Result of Placing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Result of Placing

    Manchester, UK – 5 August 2020:  Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, is pleased to confirm, further to the announcements made yesterday and earlier today, that all allocations have been confirmed by Nplus1 Singer Capital Markets Limited ( "N+1 Singer" ), and the Company  has raised gross proceeds of £16.15 million (approximately £15.0 million net of expenses) through a Placing of

    Read More
  • 5 August 2020 - Successful £16.15 million Placing & Close of Accelerated Bookbuild +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Successful £16.15 million Placing & Close of Accelerated Bookbuild

    Manchester, UK – 5 August 2020:  Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, is pleased to announce that further to the announcement made yesterday at 5.13 p.m., the Bookbuild has now closed and following strong demand, the Company expects to raise gross proceeds of £16.15 million (approximately £15.0 million net of expenses) through the

    Read More
  • 4 August 2020 - Proposed Acquisition and Placing to raise a minimum of £13 million +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Proposed Acquisition and Placing to raise a minimum of £13 million

    Manchester, UK – 4 August 2020:  Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, today announces a proposed placing (the "Placing" ) of new ordinary shares of 0.1 pence each ( "Ordinary Shares" ) in the capital of the Company (the "Placing Shares" ) at a price of 17 pence per share (the "Placing Price") to raise

    Read More
  • 3 August 2020 - CE-IVD Mark for Clarigene™ SARS-CoV-2 test +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    CE-IVD Mark for Clarigene™ SARS-CoV-2 test

    Manchester, UK – 3 August 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has achieved CE-IVD marking for its Clarigene™ SARS-CoV-2 in vitro diagnostic kit, for diagnostic use. The CE-IVD version of the Clarigene™ SARS-CoV-2 test will be used in Yourgene’s high throughput COVID-19 service lab in Manchester and will allow Yourgene to provide corporate

    Read More
  • 28 July 2020 - Final Results +

    This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

    Yourgene Health plc
    (“Yourgene”, the “Company” or the “Group”)

    Final Results

    Manchester, UK – 28 July 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its results for the year ended 31 March 2020.

    The results reflect strong organic growth as well as a first contribution from Elucigene Diagnostics (“Elucigene”), acquired in

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen